Peroxisome proliferator-activated receptors: Role of Isoform gamma in the antineoplastic effect of iodine in mammary cancer

Current Cancer Drug Targets

Volumn 11, Issue 7, 2011, Pages 775-786

  Nunez Anita R E ^a   Cajero Juarez M ^b   Aceves, C ^a  

^a INSTITUTO DE NEUROBIOLOGÍA   (Mexico)

^b Laboratorio de Biotecnología Animal   (Mexico)

Author keywords

Antineoplastic; Apoptosis; Iodine; Iodolactone; Mammary cancer; Peroxisome proliferator activated receptor (PPAR)

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ANTINEOPLASTIC AGENT; BARDOXOLONE; CELECOXIB; CIGLITAZONE; DIMETHYLBENZ[A]ANTHRACENE; FARGLITAZAR; FIBRIC ACID DERIVATIVE; ICOSANOID; IODINE; ISOPROTEIN; LY171833; METHYLNITROSOUREA; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAGAGLITAZAR; REGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CENTRAL NERVOUS SYSTEM; COLON CANCER; HUMAN; INTESTINE CANCER; LIVER CANCER; PANCREAS CANCER; PHYSIOLOGY; PROSTATE CANCER; REVIEW; STOMACH CANCER; THYROID CANCER; TUMOR GROWTH; XENOGRAFT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IODINE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN ISOFORMS;

EID: 80051678549     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911796798931     Document Type: Review

References (116)

1. Reka, A. K.; Goswami, M. T.; Krishnapuram, R.; Standiford, T. J.; Keshamouni, V. G. Molecular cross-regulation between PPAR-γ and other signaling pathways: Implications for lung cancer therapy. Lung Cancer 2011, 72, 154-159.
2. Mansure, J. J.; Nassim, R.; Kassouf, W. Peroxisome proliferatoractivated receptor γ in bladder cancer. A promising therapeutic target. Cancer Biol. Ther. 2009, 8, 1-9.
3. Peraza, M. A.; Burdick, A. D.; Marin, H. E.; Gonzáles, F. J.; Peters, J.M. The toxicology of ligands for Peroxisome proliferatoractivated receptors (PPAR). Toxicol. Sci. 2006, 90, 269-295.
4. Iacobazzi, V.; Convertini, P.; Infantino, V.; Scarcia, P.; Todisco, S.; Palmieri, F. Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression. Biochem. Biophys. Res. Commun. 2009, 388, 643-647.
5. Isseman, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 6294, 645-650.
6. Forman, B. M.; Chen, J.; Evans, R. M. Hypolipidemic drugs, poliinsaturated fatty acids, and eicosanoids are ligands for peroxisome prolifereator-activated receptors alpha and delta. Proc. Natl. Acad. Sci.USA. 1997, 94, 4312-4317.
7. Krey, G.; Braissant, O.; Horset, L. O.; Kalkhoven, E.; Perroud, M.; Parker, M. G.; Whali, W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 1997, 11, 779-790.
8. Bishop-Bailey, D.; Wray, J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostag. Other. Lipid. Mediat. 2003, 71, 1-22.
9. Aoyama, T.; Peters, J. M.; Iritani, N.; Nakajima, T.; Furihata, K.; Hashimoto, T. Altered constitutive expression of fatty acidmetabolizing enzymes in mice lacking the peroxisome proliferatoractivated receptor alpha (PPARalpha). J. Biol. Chem. 1998, 273, 5678-5684.
10. Leibowitz, M. D.; Fiévet, C.; Hennuyer, N.; Peinado-Onsurbe, J.; Duez, H.; Berbera, J.; Cullinan, C. A.; Sparrow, C. P.; Baffic, J.; Berger, G. D.; Santini, C.; Marquis, R. W.; Tolman, R. L.; Smith, R. G.; Moller, D. E.; Auwerx, J. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett. 2000, 473, 333-336.
11. Peters, J. M.; Gonzalez, F. J. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPAR β/δ) in cell proliferation and cancer. Biochim. Biophys. Acta 2009, 1796, 230-241.
12. Gelman, L.; Fruchart, J. C.; Auwerx, J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell. Mol. Life Sci. 1999, 55, 932-943.
13. Westerink, J.; Visseren, F. Pharmacological and nonpharmacological interventions to influence adipose tissue function. Cardiovasc. Diabetol. 2011, 10, 13-18.
14. Samid, D.; Wells, M.; Greene, M. E.; Shen, W.; Palmer, C. N.; Thibault, A. Peroxisome proliferator -activated receptor γ as a novel target in cancer therapy: Binding and activation by aromatic fatty acid with clinical antitumoral activity. Clin. Cancer Res. 2000, 6, 933-941.
15. Sertznig, P.; Seifert, M.; Tilgen, W.; Reichrath, J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J. Cell. Physiol. 2007, 212, 1-12.
16. Tontonoz, P.; Hu, E.; Spiegelman, B. M. Stimulation of adipogenesis in fibroblast by PPAR γ 2, a lipid-activated transcription factor. Cell 1994, 79, 1147-1156
17. Nagy, L.; Tontonoz, P.; Alvarez, J. G.; Chen, H.; Evans, R. M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998, 93, 229-240.
18. McIntyre, T. M.; Pontsler, A. V.; Silva, A. R.; St Hilaire, A.; Xu, Y.; Hinshaw, J. C.; Zimmerman, G. A.; Hama, K.; Aoki, J.; Arai, H.; Prestwich, G. D. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellularPPARgamma agonist. Proc. Natl. Acad. Sci. USA. 2003, 100, 131-136.
19. Bishop-Bailey, D.; Hla, T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J. Biol. Chem. 1999, 274, 17042-17048.
20. Wang, T.; Xu, J.; Yu, X.; Yang, R.; Han, Z. C. Peroxisome proliferator-activated receptor gamma in malignant diseases. Critical Reviews in Oncology/Hematology 2006, 58,1-14
21. Walczak, R.; Tontonoz, P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J. Lipid Res. 2002, 43,177-86.
22. Yang, F. G.; Zhang, Z. W.; Xin, D. Q.; Shi, C. J.; Wu, J. P.; Guo, Y. L.; Guan, Y. F. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta. Pharmacol. Sin. 2005, 26, 753-761.
23. Yin, F.; Wakino, S.; Liu, Z.; Kim, S.; Hsueh, W.; Collins, A.; Herle, A.; Law, R. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem. Biophys. Res. Commun. 2001, 286, 916-922.
24. Butts, B.; Tran, N.; Briehl, M. Identification of a functional peroxisome proliferators activated receptor response element in the 3'untranslated region of the human bcl-2 gene. Int. J. Oncol. 2004, 24, 1305-1310.
25. Subbaramaiah, K.; Lin, D. T.; Hart, J. C.; Dannenberg, A. J. Peroxisome proliferator-activated receptor _ ligands suppress the transcriptional activation of cyclooxygenase-2. J. Biol. Chem. 2001, 276, 12440-12448.
26. Girnun, G. D.; Domann, F. E.; Moore, S. A.; Robbins, M. E. C. Identification of a functional peroxisome proliferator- activated receptor response element in the rat catalase promoter. Mol. Endocrinol. 2002, 16, 2793-2801.
27. Yamada, K. M.; Araki, M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell. Sci. 2001, 114, 2375-2382.
28. Martin H. Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. Mutat. Res. 2010, 690, 57-63.
29. Kim, K. Y.; Cho, H. S.; Jung, W. H.; Kim, S. S.; Cheon, H. G. Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferatoractivated receptor-gamma signaling in adipocytes and myotubes. Mol. Pharmacol. 2007, 71, 1554-1562.
30. Han, S.; Sidell, N.; Fisher, P. B.; Roman, J. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor in human lung carcinoma cells. Clin. Cancer Res. 2004, 10, 1911-1919.
31. Chaffer, C. L.; Thomas, D. M.; Thompson, E. W.; Williams, E. D. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006, 6, 53-61.
32. Shiau, C. W.; Yang, C. C.; Kulp, S. K.; Chen, K. F.; Chen, C. S.; Huang, J. W.; Chen, C. S. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res. 2005, 65, 1561-1569.
33. Elrod, H. A.; Sun, S. Y. PPARgamma and apoptosis in cancer. PPAR Res. 2008, 1155, 1-12
34. Peraldi, P.; Xu, M.; Spiegelman, B. M. Thiazolidinediones block tumor necrosis factor alpha- induced inhibition of insulin signaling. J. Clin. Invest. 1997, 100, 1863-1869.
35. Kostadinova, R.; Wahli, W.; Michalik, L. PPARs in diseases: control mechanisms of inflammation. Curr. Medicinal Chem. 2005, 12, 2995-3009.
36. Barak, Y.; Nelson, M. C.; Ong, E. S.; Jones, Y. Z.; Ruiz-Lozano, P.; Chien, K. R.; Koder, A.; Evans, R. M. PPARgamma is required for placental, cardiac and adipose tissue development. Molecular cell. 1999, 4, 585-595.
37. Xin, X.; Yang, S.; Kowalski, J.; Gerritsen, M. E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 1999, 274, 9116-9121
38. Marx, N.; Duez, H.; Fruchart, J. C.; Staels, B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circulation Res. 2004, 94, 1168-1178.
39. Panigrahy, D.; Singer, S.; Shen, L. Q.; Butterfield, C. E.; Freedman, D. A.; Chen, E. J.; Moses, M. A.; Kilroy, S.; Duensing, S.; Fletcher, C.; Fletcher, J. A.; Hlatky, L.; Hahnfeldt, P.; Folkman, J.; Kaipainen, A. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 2002, 110, 923-32.
40. Chattopadhyay, N.; Singh, D. P.; Heese, O.; Godbole, M. M.; Sinohara, T.; Black, P. M.; Brown, E. M. Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPAR gamma agonist as inducers of apoptosis. J. Neuroci. Res. 2000, 61, 67-74.
41. Papi, A.; Roccihi, P.; Ferreri, A.M.; Guerra, F.; Orlandi, M. Enhanced effects of PPARgamma ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells. Oncol. Rep. 2009, 4, 1083-1089.
42. Zander, T.; Kraus, J. A.; Grommes, C.; Schlegel, U.; Feinstein, D.; Klockgether, T.; Landreth, G.; Koenigsknecht, J.; Heneka, M. T. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPAR. J. Neurochem. 2002, 81, 1052-1060.
43. Grommes, C.; Landreth, G. E.; Sastre, M.; Beck, M.; Feinstein, D. L.; Jacobs, A. H. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor agonist treatment. Mol. Pharmacol. 2006, 70, 1524-1533.
44. Benedetti, E.; Galzio, R.; Cinque, B.; Biordi, L.; D'Amico, M. A.; D'Angelo, B.; Laurenti, G.; Ricci, A.; Festuccia, C.; Cifone, M. G.; Lombardi, D.; Cimini, A. Biomolecular characterization of human glioblastoma cells in primary cultures: differentiating and antiangiogenic effects of natural and synthetic PPARgamma agonists. J. Cell. Physiol. 2008, 217, 93-102.
45. Han, S. W.; Greene, M. E.; Pitts, J.; Wada, R. K.; Sidell, N. Novel expression and function of peroxisome proliferator- activated receptor gamma (PPAR gamma) in human neuroblastoma cells. Clin. Cancer Res. 2001, 7, 98-104.
46. Rohn, T. T.; Wong, S. M.; Cotman, C. W.; Cribbs, D. H. 15-deoxydelta 12,14-prostaglandin J2, a specific ligand for peroxisome proliferators-activated receptor gamma, induces neuronal apoptosis. Neuroreport 2001, 12, 839-843.
47. Burdge, C. G.; Rodway, H.; Kohler, J. A.; Lillycrop, K. A. Effect of fatty-acid supplementation on growth and differentiation of human IMR-32 neuroblastoma cells in vitro. J. Cell. Biochem. 2000, 80, 266-273.
48. Rodway, H. A.; Hunt, A. N.; Kohler, J. A.; Postle, A. D.; Lillycrop K. A. Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor _ activation induced by 15-deoxy delta12, 14-prostaglandin J2 in neuroblastoma cells. Biochem. J. 2004, 382, 83-91.
49. Emmans, V. C.; Rodway, H. A.; Hunt, A. N.; Lillycrop, K. A. Regulation of cellular proceses by PPARgamma ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression. Biochem. Soc. Trans. 2004, 32, 840-842.
50. Morosetti, R.; Servidei, T.; Mirabella, M.; Rutella, S.; Mangiola, A.; Maira, G.; Mastrangelo, R.; Koeffler, H. P. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int. J. Oncol. 2004, 2, 493-502.
51. Cellai, I.; Benvenuti, S.; Luciani, P.; Galli, A.; Ceni, E.; Simi, L.; Baglioni, S.; Muratori, M.; Ottanelli, B.; Serio, M.; Thiele, C. J.; Peri, A. Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells. Br. J. Cancer 2006, 95, 879-888.
52. Lefebvre, A. M.; Chen, I.; Desreumaux, P.; Najib, J.; Fruchart, J. C.; Geboes, K.; Briggs, M.; Heyman, R.; Auwerx, J. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 1998, 4, 1053-1057.
53. Chen, G. G.; Lee, J. F.; Wang, S. H.; Chan, U. P.; Ip, P. C.; Lau, W. Y. Apoptosis induced by activation of peroxisome proliferatoractivated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life. Sci. 2002, 70, 2631-2646.
54. Wang, D.; Dubois, R. N. Peroxisome proliferator-activated receptors and progression of colorectal cancer. PPAR Res. 2008, doi: 10.1155/2008/931074.
55. Fujisawa, T.; Sugiyama, M.; Tomimoto, A.; Wada, K.; Endo, H.; Takahashi, H.; Yoneda, K.; Yoneda, M.; Inamori, M.; Saito, S.; Terauchi, Y.; Kadowaki, T.; Tsuchiya, N.; Nakagama, H.; Nakajima, A. Inhibition of peroxisome proliferator-activated receptor γ promotes tumorigenesis through activation of the-catenin/T cell factor (TCF) pathway in the mouse intestine. J. Pharmacol. Sci. 2008, 108, 535-544.
56. Sato, H.; Ishihara, S.; Kawashima, K.; Moriyama, N.; Suetsugu, H.; Kazumori, H.; Okuyama, T.; Rumi, M. A.; Fukuda, R.; Nagasue, N.; Kinoshita, Y. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br. J. Cancer 2000, 83, 1394-1400.
57. Chen, Y. X.; Zhong, X. Y.; Qin, Y. F.; Bing, W.; He, L. Z. 15d- PGJ2 inhibits cell growth and induces apoptosis of MCG-803 human gastric cancer cell line. World J. Gastroenterol. 2003, 9, 2149-2153.
58. Lu, J.; Imamura, K.; Nomura, S.; Mafune, K.; Nakajima, A.; Kadowaki, T.; Kubota, N.; Terauchi, Y.; Ishii, G.; Ochiai, A.; Esumi, H.; Kaminishi, M. Chemopreventive effect of peroxisome proliferator-activated receptor on gastric carcinogenesis in mice. Cancer Res. 2005, 65, 4769-4774.
59. Elnemr, A.; Ohta, T.; Iwata, K.; Ninomia, I.; Fushida, S.; Nishimura, G.; Kitagawa, H.; Kayahara, M.; Yamamoto, M.; Terada, T.; Miwa, K. PPAR gamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int. J. Oncol. 2000, 17, 1157-1164.
60. Itami, A.; Watanabe, G.; Shimada, Y.; Hashimoto, Y., Kawamura, J.; Kato, M.; Hosotani, R.; Imamura, M. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int. J. Cancer 2001, 94, 370-376.
61. Toyoda, M.; Takagi, H.; Horiguchi, N.; Kakizaki, S.; Sato, K.; Takayama, H.; Mori, M. A ligand for peroxisome proliferatoractivated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 2002, 50, 563-567.
62. Zhou, Y. M.; Wen, Y. H.; Kang, X. Y.; Oian, H. H.; Yang, J. M.; Yin, Z. F. Troglitazone, a Peroxisome proliferator-activated receptor gamma ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World. J. Gastroenterol. 2008, 14, 2168-2173.
63. Cheng, J.; Nakamura, H.; Imanishi, H.; Liu, W.; Morisaki, T.; Sugiyama, T.; Hada, T. Peroxisome proliferator-activated receptor gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2, and ciglitazone, induce growth inhibition and cell cycle arrest in hepatic oval cells. Biochem. Biophys. Res. Commun. 2004, 322, 458-464.
64. Ohta, K.; Endo, T.; Haraguchi, K.; Hershman, J. M.; Onaya, T. Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2001, 86, 2170-2177.
65. Bonofiglio, D.; Qi, H.; Gabriele, S.; Catalano, S.; Aquila, S.; Belmonte, M.; Andò, S. Peroxisome proliferator-activated receptor inhibits follicular and anaplasic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. Endocr. Relat. Cancer 2008, 15, 545-557.
66. Martelli, M. L.; Iuliano, R.; Le Pera, I.; Sama, I.; Monaco, C.; Cammarota, S.; Kroll, T.; Chiariotti, L.; Santoro, M.; Fusco, A. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J. Clin. Endocrinol. Metab. 2002, 87, 4728-4733.
67. Kroll, T. G.; Sarraf, P.; Pecciarini, L.; Chen, C. J.; Mueller, E.; Spiegelman, B. M.; Fletcher, J. A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 2000, 289, 1357-1360.
68. Espadinha, C.; Cavaco, B. M.; Leite, V. PAX8PPARgamma stimulates cell viability and modulates expression of thyroidspecific genes in a human thyroid cell line. Thyroid 2007, 17, 497-509.
69. Fröhlich, E.; Machicao, F.; Wahl, R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr. Relat. Cancer 2005, 12, 291-303.
70. Golias, Ch.; Iliadis, I.; Peschos, D.; Charalabopoulos, K. Amplification and co-regulators of androgen receptor gene in prostate cancer. Exp. Oncol. 2009, 31, 3-8.
71. Segawa, Y.; Yoshimura, R.; Hase, T.; Nakatani, T.; Wada, S.; Kawahito, Y.; Kishimoto, T.; Sano, H. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. The Prostate 2002, 51, 108-116.
72. Kubota, T.; Koshizuka, K.; Williamson, E. A.; Asou, H.; Said, J. W.; Holden, S.; Miyoshi, I.; Koeffler, H. P. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumoral effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998, 58, 3344-3352.
73. Maggiora, M.; Bologna, M.; Cerù, M. P.; Possati, L.; Angelucci, A.; Cimini, A.; Miglietta, A., Bozzo, F.; Margiotta, C.; Muzio, G.; Canuto, R. A. An overview of the effect of linoleic and conjugatedlinoleic acids on the growth of several human tumor cell lines. Int. J. Cancer. 2004, 112, 909-919.
74. Laidler, P.; Duli-ska, J.; Mrozicki, S. Does the inhibition of c-myc expression mediate the anti-tumor activity of PPAR's ligands in prostate cancer cell lines? Arch. Biochem. Biophys. 2007, 462, 1-12.
75. Mueller, E.; Smith, M.; Sarraf, P.; Kroll, T.; Aiyer, A.; Kaufman, D. S.; Oh, W.; Demetri, G.; Figg, W. D.; Zhou, X. P.; Eng, C.; Spiegelman, B. M.; Kantoff, P. W. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc. Natl. Acad. Sci. USA. 2000, 97, 10990-10995.
76. Lyles, B. E.; Akinyeke, T. O.; Moss, P. E.; Stewart, L.V. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPAR γ-dependent and PPAR γ-independent pathways. Cell Cycle 2009, 8, 268-277.
77. Matsuyama, M.; Yoshimura, R. The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer. Biologics. 2008, 4, 725-732.
78. Tikoo, K.; Kumar, P.; Gupta, J. Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7,12-dimethyl benzanthracene (DMBA) induced breast cancer rats. BMC Cancer 2009, 9, 107-111.
79. Yin, Y.; Russell, R. G.; Dettin, L. E.; Bai, R.; Wei, Z. L.; Kozikowski, A. P.; Kopelovich, L.; Glazer, R. I. Peroxisome proliferator-activated receptor δ and γ agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 2005, 65, 3950-3957.
80. Metha, R. G.; Williamson, E.; Patel, M. K.; Koeffler, H.P. A ligand of Peroxisome proliferator-activated receptor, retinoids, and prevention of preneoplastic mammary lesions. J. Natl. Cancer Inst. 2000, 92, 418-423.
81. Suh, N., Wang, Y.; Williams, C. R.; Risingsong, R.; Gilmer, T.; Willson, T. M.; Sporn, M. B. A new ligand for the Peroxisome proliferator-activated receptor γ (PPAR γ), GW7845, inhibits rat mammary carcinogenesis. Cancer. Res. 1999, 59, 5671-5673.
82. Badawi, A.F.; Eldeen, M.B.; Liu, Y.; Ross, E.A.; Badr, M.Z. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferatorsactivated receptor. Cancer Res. 2004, 64, 1181-1189.
83. Howe, L. R.; Subbaramaiah, K.; Brown, A. M. C.; Dannenberg, A. J. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr. Related Cancer 2001, 8, 97-114.
84. Wang, D.; Dubois, R. N. Eicosanoids and cancer. Nat Rev Cancer. 2010, 10, 181-93.
85. Elstner, E.; Müller, C.; Koshizuka, K.; Williamson, E. A.; Park, D.; Asou, H.; Shintaku, P.; Said, J. W.; Heber, D.; Koeffler H. P. Ligand for peroxisome proliferator-activated receptor _ and retinoic acid receptor inhibits growth and induces apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad.USA. 1998, 95, 8806-881.
86. Clay, C. E.; Namen, A. M.; Atsumi, G.; Willingham, M. C.; High, K. P.; Kute, T. E.; Trimboli, A. J.; Fonteh, A. N.; Dawson, P. A.; Chilton, F. H. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 1999, 20, 1905-1911.
87. Mustafa, A.; Kruger, W. D. Suppression of tumor formation by a cyclooxigenase-2 inhibitor and a Peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clin. Cancer Res. 2008, 14, 4935-4942.
88. Keller, H.; Givel, F.; Perroud, M.; Wahli, W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol. Endocrinol. 1995, 9, 794-804.
89. Bocca, C.; Bozzo, F.; Francisa, S.; Colombatto, S.; Miglietta, A. Involvement of PPAR gamma and E-cadherin/beta -catenin pathway in the antiproliferative effect of conjugated linoleic acid in MCF-7 cells. Int. J. Cancer 2007, 121, 248-256.
90. Bonofiglio, D.; Gabriele, S.; Aquila, S.; Qi, H.; Belmonte, M.; Catalano S, Andó S. Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells. Breast Cancer Res. Treat. 2009, 113, 423-434
91. Rubenstrunk A, Hanf R, Hum D.W., Fruchart J.C., Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochem Biophys. Acta 2007, 1771, 1065-1081.
92. Burstein, H. J.; Demetri, G. D.; Mueller, E.; Sarraf, P.; Spiegelman, B. M.; Winer, E. P. Use of the peroxisome proliferator-activated receptor (PPAR)gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res. Treat. 2003, 79, 391-397.
93. Yee, L. D.; Williams, N.; Wen, P.; Young, D. C.; Lester, J.; Johnson, M. V.; Farrar, W. B.; Walker M. J.; Povoski, S. P.; Suster, S.; Eng, C. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin. Cancer Res. 2007, 13, 246-252.
94. Kodama, M.; Kodama, T. Parallel comparison of chronological risk changes among cancers of the breast, the uterine cervix and the stomach, as tested in 9 female populations of the world from early 1960s to mid 1980s: a stochastic study. Int. J. Mol. Med. 2003, 12, 369-78.
95. World Health Organization. The global burden of disease: 2004 update. Geneva: World Health Organization, 2008.
96. Mettlin, C. Global breast cancer mortality statistics. CA. Cancer J. Clin. 1999, 49, 138-144.
97. Cann, S. A.; Van Netter, J. P.; Van Netter, C. Hypothesis: Iodine, selenium and the development of breast cancer. Cancer Causes Contr. 2000, 11, 121-127.
98. Venturi, S.; Donati, F.; Venturi, A.; Venturi, M.; Grossi, L.; Guidi, A. Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach. Adv. Clin. Path. 2000, 4, 11-17.
99. Aceves, C.; Anguiano, B. Is iodine an antioxidant and antiproliferative agent for the mammary and prostate glands? In: Comprehensive Handbook of Iodine. Nutritional, endocrine and pathological aspects. V. R. Preedy; G. N. Burrow; R. R. Watson, Eds. Academic Press. New York 2009 Chap 26, pp. 249-257.
100. Ghent, W. R.; Eskin, B. A.; Low, D. A.; Hill, L. P. Iodine replacement in fibrocystic disease of the breast. Cancer J. Surgery 1993, 36, 453-460.
101. Kessler, J. H. The efffect of supraphysiologic levels of iodine on patients with cyclic mastalgia. The Breast J. 2004, 10, 328-336.
102. García-Solís, P.; Alfaro, Y.; Anguiano, B.; Delgado, G.; Guzmán, R. C.; Nandi, S.; Díaz-Muñoz, M.; Aceves, C. Inhibition of Nmethyl-N-nitrosourea induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) treatment evidence that I2 prevents cancer promotion. Mol. Cell. Endocrinol. 2005, 236, 49-57.
103. Arroyo-Helguera, O.; Delgado, G.; Anguiano, B.; Aceves, C. Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line. Endocr. Related Cancer 2006, 13, 1147-1158.
104. Rösner, H.; Torremante, P.; Möller, W.; Gärtner, R. Antiproliferative/cytotoxic activity of molecular iodine and iodolactones in various human carcinoma cell lines. No interfering with EGF-signaling, but evidence for apoptosis. Exp. Clin. Endocrinol. Diabetes 2010, 117, 1-10
105. Pisarev, M.; Krawiec, L.; Juvenal, G.; Bocanera, L.; Pregliasco, L.; Sartorio, G.; Cheste, H. Studies on the goiter inhibiting action of iodolactones. Eur. J. Pharmacol. 1994, 258, 33-37.
106. Langer, R.; Burzler, C.; Bechtner, G.; Gartner, R. Influence of iodide and iodolactones on thyroid apoptosis. Evidence that apoptosis induced by iodide is mediated by iodolactones in intact porcine thyroid follicles. Exp. Clin. Endocrinol. Diabetes 2003, 111, 325-329.
107. Smyth, P. Role of iodine in antioxidant defence in thyroid and breast disease. Biofactors 2003, 19, 121-130.
108. Zhang, L.; Sharma, S.; Zhu, L.; Kogai, T.; Hershman, J.; Brent, G.; Dubinett, S.; Huang, M. Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells. Cancer Res 2003, 63, 5065-5072.
109. Arroyo-Helguera, O.; Rojas, E.; Delgado, G.; Aceves, C. Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects. Endocr. Related. Cancer 2008, 15, 1003-101
110. Shrivastaba, A.; Tiwari, M.; Sinha, R. A.; Kumar, A.; Balapure, A. K.; Bajpai, V. K.; Sharma, R.; Mitra K.; Tandon A.; Godbole, M. M. Molecular iodine induces caspase- independent apoptosis in human breast carcinoma cells involving mitochondria- mediated pathway. J. Biol. Chem. 2006, 281, 19762-19771.
111. Gärtner, R.; Rank, P.; Ander, B. The role of iodine and deltaiodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. Hormones (Athens). 2010, 9, 60-66.
112. Aceves, C.; García-Solís, P.; Arroyo-Helguera, O.; Vega-Riveroll, L.; Delgado, G.; Anguiano, B. Antineoplastic effect of iodine in mammary cancer. Participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR). Mol. Cancer 2009, 8, 33-36.
113. Rillema, J. A.; Mulder, J. A. Arachidonic acid distribution in lipids of mammary glands and DMBA-induced tumors of rats. Prostaglandins Med. 1978, 1, 31-38.
114. Nicholson, M. L.; Neoptolemos, J. P.; Clayton, H. A.; Talbot, I. C.; Bell, P. R. Increased cell membrane arachidonic acid in experimental colorectal tumours. Gut 1991, 4, 413-418.
115. Sigal, E. The molecular biology of mammalian arachidonic and metabolism. Am. J. Phys. 1991, 260, L13-L28
116. Nuñez-Anita, R. E.; Arroyo-Helguera, O.; Cajero-Juárez, M.; López-Bojorquez, L.; Aceves, C. A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplastic effect of iodine in mammary cancer. Prostag. Other Lipid Mediat. 2009, 89, 34-42.